AI assistant
Sending…
Immuneering Corp — Director's Dealing 2025
Oct 7, 2025
32973_dirs_2025-10-07_0f1bbb73-2318-4daa-828c-6e118ebe2af9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2025-10-03
Reporting Person: Feinberg Peter (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-10-03 | Class A Common Stock | P | 7500 | $6.67 | Acquired | 156766 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Class A Common Stock | 392242 | Indirect |
| Class A Common Stock | 476615 | Indirect |
| Class A Common Stock | 115441 | Indirect |
More from Immuneering Corp
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Major Shareholding Notification
2026
Jan 22